Logicbio Therapeutics is UNDERVALUED at 7.51 per share with modest projections ahead.
We provide investment recommendation to complement the last-minute
expert consensus on Logicbio Therapeutics. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of LogicBio Therapeutics? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
How important is LogicBio Therapeutics's Liquidity
LogicBio Therapeutics
financial leverage refers to using borrowed capital as a funding source to finance LogicBio Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. LogicBio Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to LogicBio Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of LogicBio Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between LogicBio Therapeutics's total debt and its cash.
Is Logicbio a risky opportunity?
Let's check the volatility. Logicbio is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Logicbio (NASDAQ:LOGC) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. taking in a share of a Logicbio Therapeutics stock makes you a part-owner of that company.
Logicbio Therapeutics Current Consensus
Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Logicbio Therapeutics. The Logicbio consensus assessment is calculated by taking the average estimates from all of the analysts covering Logicbio Therapeutics
| Strong Buy | 5 | 100.0 |
| Buy | 0 | 0.0 |
| Hold | 0 | 0.0 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Will Logicbio slip impact its fundamentals?
Current mean deviation is at 2.4. Logicbio Therapeutics shows above-average downside volatility for the selected time horizon. We advise investors to inspect Logicbio Therapeutics further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Logicbio Therapeutics future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Logicbio Therapeutics' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Logicbio Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
The Current Takeaway on Logicbio Therapeutics Investment
When is the right time to buy or sell Logicbio Therapeutics? Buying stocks such as Logicbio Therapeutics isn't very hard. However, what challenging for most investors is doing it at the right time. Proper
market timing is something most people cannot do without
sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily basis.
All things considered, as of the 25th of September 2021, we believe that Logicbio Therapeutics is currently
undervalued with
significantly high odds of financial distress in the next two years. Our primary 90 days advice on the company is
Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of LogicBio Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
